Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant as PONV Prevention

• Status: Not yet recruiting
• Trial end date: 2024-03-22
• Target enrollment: 0
• Participant gender: Female

Summary

As a preventive for postoperative nausea and vomiting in patients undergoing laparoscopic gynecological surgery, we shall investigate the efficacy of the triple therapy of dexamethasone, palonosetron, and fosaprepitant comparing to dual therapy of dexamethasone and palonosetron.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria:

• Patients undergoing laparoscopic gynecological surgery.

• Adults between the ages of 18 and 50

• American Society of Anesthesiologists Physical Status (ASA physical status I, II

Exclusion Criteria:

• American Association of Anesthesiologists physical standards (ASA physical status III or higher)

• Children under the age of 19

• Adults over 49 years of age

• Diabetes Mellitus

• Pregnant or lactating women

• Patients with a history of allergy or contraindications for use of the study drug

• Patients who did not understand this study or expressed their refusal.

• Patients with a history of serious psychologic disease that may affect the patient evaluation

• Patients taking serotonergic drugs